Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2016
- Source ID
- 10.1016/j.bbmt.2016.08.016
Entities
People
- Brent R. Logan
- Heather S.l. Jim
- J. Douglas Rizzo
- Jennifer Le-Rademacher
- Jennifer M. Knight
- John R Wingard
- Karen L. Syrjala
- Laura Rawls
- Mary M. Horowitz
- Michael J Martens
- Mingwei Fei
- Muneer H Abidi
- Navneet S Majhail
- Paul B. Jacobsen
- Stephanie J. Lee
- William A. Wood
Organizations
- Alexion Pharmaceuticals
- Amgen
- Astellas Pharma (United States)
- AstraZeneca
- AstraZeneca (United States)
- Bristol-Myers Squibb
- Celgene
- Chiron Corporation
- Elevance Health, Inc.
- Fred Hutchinson Cancer Center
- Genzyme
- Gilead Sciences
- Health Research
- Health Resources and Services Administration
- HistoGenetics (United States)
- Incyte
- Janssen Scientific Affairs (United States)
- Jazz Pharmaceuticals
- Leukemia & Lymphoma Society
- Medac
- Medical College of Wisconsin
- Merck & Co.
- Miltenyi Biotec
- National Cancer Institute
- National Center for Advancing Translational Sciences
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National Marrow Donor Program
- Office of Naval Research
- Onyx Pharmaceuticals
- Otsuka (United States)
- Patient-Centered Outcomes Research Institute
- Pfizer
- Roche (United States)
- Roswell Park Comprehensive Cancer Center
- Sanofi-Aventis
- Seagen
- Spectrum Pharmaceuticals
- St. Baldrick's Foundation
- Swedish Orphan Biovitrum
- Takeda Oncology
- University of Minnesota